Skip to main content

Table 2 Comparison of stimulation and cycle outcomes in the two study groups

From: Does the “delayed start” protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial

Variablesa Delayed start group (N = 60) Control group (N = 60) 95% CI P value
Total rFSH dose (IU) 2210.0 ± 559.4 2897.0 ± 952.0 (− 969.8–405.1) < 0.001
Total hMG dose (IU) 1122.5 ± 272 1487 ± 486 (− 507.4–222.5) < 0.001
Duration of stimulation (day) 9.3 ± 1.7 12.3 ± 3.6 (− 3.9–1.8) < 0.001
No. of retrieved oocytes 3.2 ± 2.7 2.0 ± 2.1 (0.22–2.0) 0.01*
No. of metaphase II oocytes 2.5 ± 2.2 1.8 ± 1.9 (−0.06–1.4) 0.07
The cases with no oocyte result, n (%) 6 (10) 2 (3.4) 0.1
Cancellation rate (no response), n (%) 0 (0) 18 (30.0) < 0.001
Fertilization rate 73.4 ± 36.3 42.6 ± 36.7 (15.4–46.0) < 0.001*
No. of obtained embryos 2.3 ± 1.6 1.7 ± 0.8 (−0.07–1.2) 0.02*
No. of top quality embryo 1.5 ± 1.3 1.0 ± 0.7 (−0.06–1.0) 0.02*
The cases with no embryo result, n (%) 8 (13.3) 12 (20.0) 0.3
No. of embryos transferred 1.8 ± 0.9 1.7 ± 0.8 (−0.04–0.5) 0.7
Endometrial thickness at trigger (mm) 9.3 ± 1.2 8.7 ± 0.9 (0.12–0.96) 0.01*
Implantation rate 41.6 (33.3–50) 50 (50–50) 0.5
Clinical pregnancy/ ET (%) 4/46 (8.7) 2/28 (7.1) 0.8
Miscarriage rate/ET (%) 0 (0) 1 (3.5) 0.1
  1. aDescriptive data were presented by mean ± standard deviation and median (interquartile range) as indicated. The binary variables were presented as number (percent). CI: confidence interval of the difference, *P-value ≤0.05 was considered statistically significant. hMG human menopause gonadotropin, rFSH recombinant follicle stimulating hormone, No number. ET embryo transfer